INTRODUCTION
Lenalidomide is a novel oral immunomodulatory derivative of thalidomide with potent activity and with a much improved toxicity profile to the parent compound. Thalidomide has a potential to treat inflammatory and neoplastic condition like multiple myeloma but was withdrawn from the market after its teratogenic effects were established. 1 Lenalidomide, a potent analogue of thalidomide was developed with improvement in safety and efficacy than the parent drug, thalidomide.It was created using thalidomide as a template by adding an amino group to the 4th carbon of the phthaloyl ring and removal of a carbonyl group.
Lenalidomide possesses immunomodulatory, antiangiogenic, antineoplastic and anti-inflammatory activities. Lenalidomide has been extensively studied and approved for refractory / relapsing multiple myeloma (MM), mantle cell lymphoma (MCL) and myelodysplastic syndromes (MDS). 2 Multiple myeloma is a B cell malignancy characterized by accumulation of plasma cell clone in the bone marrow, monoclonal protein in serum and/or urine, reduced immunoglobulin levels and lytic bone disease. 3 Alkylating agents, anthracyclines and corticosteroids were commonly used drugs in multiple myeloma which extended patient's survival to median 3-4 yearsas compared to median survival of 4-5 years with high dose of these drugs followed by autologous transplantation. 4 Due to the development of tumor cell resistance to all therapies, multiple myeloma still remains incurable, requiring further study on novel treatment strategies. 5 The survival in MM patients has improved significantly in the past decade due to the introduction of novel agents including immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide), proteasome inhibitors (bortezomib, carfilzomib, marizomib and ixazomib citrate), monoclonal antibodies (elotuzumab, siltuximab, daratumumab and BT-062), and drugs affecting an interaction with the tumor microenvironment (anti-VLA4 monoclonal antibody, chemokine CXCR4 inhibitor AMD-3100 and selectin inhibitor GMI-1070). [6] [7] [8] Lenalidomide has been found to be more potent in the stimulation of T-cell proliferation and INF gamma and IL-2 production than thalidomide, whereas both thalidomide and pomalidomide, another thalidomide analogue, have been found to be more potent at inhibiting sprout formation than lenalidomide when antiangiogenic properties were assessed in a human umbilical explant model. Thalidomide was associated with dose-limiting toxicities including somnolence, constipation, neuropathy, and increased incidence of venothromboembolism (VTE), especially when combined with dexamethasone 9 .No clinical trials directly comparing these agents have been performed, lenalidomide appears to have a lower incidence of constipation, peripheral neuropathy, and somnolence than thalidomide. 
Pharmacokinetics
Lenalidomide is rapidly absorbed following oral administration and food has no change in AUC but Cmax may be reduced to 36%. Plasma protein binding is approximately 30%. Lenalidomide -undergoes limited metabolism with two identified metabolites hydroxylenalidomide and n-acetyl-lenalidomide; each constitutes less than 5% of parent drug levels in circulation. Unchanged lenalidomide, about 67%, is the predominant circulating component primarily excreted by renal route. The mean half-life of lenalidomide is 3 hours in healthy subjects and 3 to 5 hours in patients with MM, MDS or MCL.
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Clinical efficacy
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) conducted to assess the efficacy, safety, and pharmacokinetics of lenalidomide plus low-dose dexamethasone showed high response rate and acceptable safety profile in heavily pretreated Chinese patients with RRMM, including those with renal impairment and IgD subtype. 15, 16 Two phase III randomized studies validated the role of lenalidomide in combination with dexamethasone for the treatment of relapsed/refractory MM patients showed overall response rate of 83%, including 29% of complete response as seen by negative immunofixation on the serum and urine. 17 The toxicity profile of the treatment was in line with that reported in previous studies and led to dose reductions and treatment interruption in 44% and 17% of patients, respectively. 18 These results led the US In a phase I clinical dose-escalation (5 mg/day, 10 mg/day, 25 mg/day, and 50 mg/day) study of lenalidomideat Dana-Farber cancer institute, no doselimiting toxicity (DLT) was observed in patients treated at any dose level within the first 28 days; however, grade 3 myelosuppression developed after day 28 in all 13 patients treated with 50 mg/day lenalidomide. Dose reduction to 25 mg/day was well tolerated in 12 patients and therefore considered to be the maximal tolerated dose (MTD). Most importantly, no significant somnolence, constipation, or neuropathy, the most common toxicities of thalidomide, has been seen in any cohort.
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A multicentric, open-label, randomized phase II study evaluated 2 dose regimens of lenalidomide for relapsed, refractory MM with either 30 mg once-daily or 15 mg twice-daily oral lenalidomide for 21 days of every 28-day cycle. Responses were evaluated according to European group for blood and marrow transplantation (EBMT) criteria and overall response rate to lenalidomide alone was 25%; 24% for 30 mg once-daily and 29% for 15 mg twice-daily cohort. This study indicates that lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone. 
Contraindications
Thalidomide is a known human teratogen that causes life-threatening human birth defects or embryo-fetal death. Lenalidomideby being a thalidomide analogue, is contraindicated for use during pregnancy(Pregnancy category X).Women of childbearing potential are also to be cautioned for its use unless adequate precautions are taken to prevent pregnancy since it runs high risk of potential for birth defects.Hypersensitivity to this drug is absolute contraindication. 
Precautions
Other indications
Lenalidomide is an active first-line treatment option for CLL that is well-tolerated if a conservative approach with low doses and slow dose-escalation is used. 24 Many studies have been done on assessing the safety and therapeutic profile of lenalidomide in patients with cancers like acute myeloid leukemia, prostate carcinoma, renal cell carcinoma, B-cell lymphoma, astrocytoma, glioma, hepatocellular carcinoma, pancreatic cancer, etc. The lenalidomide has possibility of being used as an adjuvant in support of more specific immunotherapeutic interventions including anticancer vaccines and adoptively transferred cells which warrants further investigation. 25 Lenalidomide is undergoing clinical trial for Hodgkin's lymphoma and non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and solid tumor cancersof the pancreas. 26, 27 One Phase 3 clinical trial being conducted by Celgene in elderly patients with B-cell chronic lymphocytic leukemia was halted in July 2013 when a disproportionate number of cancer deaths were observed during treatment with lenalidomide versus patients treated with chlorambucil.
28
CONCLUSION
Lenalidomide is an important addition to the treatment armamentarium for relapsed or refractory MM, MDS and MCL. Lenalidomide is administered in combination with low-dose glucocorticoids (most often dexamethasone or prednisone), which are well known for their immunosuppressive potential. Lenalidomide is more potent, more active and less toxic than its parent drug thalidomide.
